Caribou Biosciences, Inc.
جودة البيانات: 100%
CRBU
Nasdaq
Manufacturing
Chemicals
KWD 1.93
▼
KWD 0.03
(-1.53%)
القيمة السوقية: 190.38 M
السعر
KWD 1.97
القيمة السوقية
190.38 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue grew 3.84% annually over 5 years — modest growth
Negative free cash flow of -112.35 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7.82%
النمو
Revenue Growth (5Y)
3.84%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)11.66%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-96.19%
أقل من متوسط القطاع (-53.47%)
ROIC-65.30%
Net Margin-1327.40%
Op. Margin-1329.37%
الأمان
Debt / Equity
N/A
Current Ratio5.54
Interest CoverageN/A
التقييم
PE (TTM)
-1.29
أعلى من متوسط القطاع (-1.48)
P/B Ratio1.34
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.3 | -1.5 |
| P/B | 1.3 | 1.6 |
| ROE % | -96.2 | -53.5 |
| Net Margin % | -1327.4 | -41.5 |
| Rev Growth 5Y % | 3.8 | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
8 محللين
Buy
الحالي
KWD 1.93
المستهدف
KWD 11.13
KWD 4.00
KWD 8.50
KWD 32.00
التوقعات
مكرر الربحية المستقبلي
-1.29
ربحية السهم المستقبلية
-KWD 1.50
الإيرادات المقدّرة
27.08 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.50
-KWD 1.50 – -KWD 1.50
|
27.08 M | 1 |
| FY2026 |
-KWD 1.38
-KWD 1.38 – -KWD 1.38
|
23.70 M | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.34
-KWD 0.34 – -KWD 0.34
|
2.12 M | 1 |
| 2026 Q1 |
-KWD 0.31
-KWD 0.31 – -KWD 0.31
|
2.18 M | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.32 | -KWD 0.28 | +12.9% |
| Q32025 | -KWD 0.36 | -KWD 0.30 | +16.0% |
| Q22025 | -KWD 0.42 | -KWD 0.35 | +16.7% |
| Q12025 | -KWD 0.45 | -KWD 0.44 | +2.2% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11.66% | Revenue Growth (3Y) | -43.11% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 3.84% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 11.16 M | Net Income (TTM) | -148.13 M |
| ROE | -96.19% | ROA | -71.23% |
| Gross Margin | N/A | Operating Margin | -1329.37% |
| Net Margin | -1327.40% | Free Cash Flow (TTM) | -112.35 M |
| ROIC | -65.30% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5.54 |
| Interest Coverage | N/A | Asset Turnover | 0.05 |
| Working Capital | 127.45 M | Tangible Book Value | 141.85 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.29 | Forward P/E | N/A |
| P/B Ratio | 1.34 | P/S Ratio | 17.06 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -59.02% | ||
| Market Cap | 190.38 M | Enterprise Value | 179.23 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.59 | Revenue / Share | 0.12 |
| FCF / Share | -1.16 | OCF / Share | -1.15 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 12.18% | FCF Conversion | 75.85% |
| SBC-Adj. FCF | -126.36 M | Growth Momentum | 7.82 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.16 M | 9.99 M | 34.48 M | 13.85 M | 9.60 M |
| Net Income | -148.13 M | -149.11 M | -102.07 M | -99.42 M | -66.92 M |
| EPS (Diluted) | -1.59 | -1.65 | -1.38 | -1.64 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -148.34 M | -166.62 M | -116.06 M | -106.40 M | -66.98 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 109.44 M | 130.15 M | 112.08 M | 82.23 M | 52.26 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 3.65 M | 3.93 M | 3.53 M | 1.62 M | 984,000.0 |
| Interest Expense | — | — | — | — | 8,000.0 |
| Income Tax | -550,000.0 | -9,000.0 | 193,000.0 | 70,000.0 | 321,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 175.37 M | 313.31 M | 432.21 M | 373.77 M | 442.36 M |
| Total Liabilities | 53.19 M | 60.36 M | 63.81 M | 72.89 M | 54.53 M |
| Shareholders' Equity | 122.18 M | 252.95 M | 368.40 M | 300.87 M | 387.83 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 12.36 M | 16.29 M | 51.16 M | 58.34 M | 240.42 M |
| Current Assets | 145.23 M | 219.38 M | 338.84 M | 260.25 M | 391.19 M |
| Current Liabilities | 25.41 M | 30.65 M | 28.30 M | 28.13 M | 25.83 M |
{"event":"ticker_viewed","properties":{"ticker":"CRBU","listing_kind":"stock","pathname":"/stocks/crbu","exchange":"Nasdaq","country":"US"}}
